|
|
| Welcome to EuroCSC |
|
| a Consortium funded by the European Commission to exploit Cancer Stem Cells (CSCs) as targets for anti-tumor therapy. |
|
 |
The EuroCSC Consortium consists of 6 partners. Five of these are European academic institutions and one a European biotech company. Seven Principal Investigators from these partner institutions participate in the project. |
|
The goal of their research is to identify the molecular mechanisms that allow CSCs to maintain and expand tumor, and to design drugs directed against these molecular targets that will prevent CSCs from carrying out this function.
|
|
|
|
|
|
|
|
|
|
 |
|
Focus of research within the EuroCSC |
|
 |
|
|
|
| Principal investigators, locations and research focus |
|
|
 |
Claus Nerlov, EMBL, mouse genetics and trancriptional regulation |
|
Sten EW. Jacobsen, Lund University, hematopietic and leukemic stem cells |
|
Dominique Bonnet, Cancer research UK, leukemic stem cells |
|
Ole W. Petersen, University of Copenhagen, breast cancer |
|
Tariq Enver, Medical Research Council, transcriptional reprogramming |
|
Roger Patient, Medical Research Council, developmental transcriptional networks |
|
Jon Tinsley, Vastox |
|
|
|
|
|
|
|
|
Centers affiliated with EuroCSC |
|
|
|
|
|
|
|
|
|
|
|
| News and calendar |
|
| 06-04-2008 |
| Modeling of C/EBPa mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia initiating cells. Cancer Cell 2008 13: 299-310 |
|
|
|
| 12-11-2007 |
| NOV (CCN3) functions as a regulator of human haematpoietic stem/progenitor cells. Science 2007 316 590-3 |
|
|
|
| 12-11-2007 |
| FGF controls the timing of Scl, Lmo2 and Runx1 expression during embryonic blood development. Blood 2007 111 1157-66 |
|
|
| |
|
|
|
|
|
